Overview
Mersana Therapeutics reports Q3 net loss of $7.5 mln vs $11.5 mln loss year ago
Q3 collaboration revenue drops to $11 mln from $12.6 mln
On Nov 13, Day One agreed to acquire Mersana for up to $285 mln; deal expected to close by January 2026
Outlook
Company did not provide specific financial guidance for future periods in its press release; cancels conference call to discuss business updates and results
Result Drivers
CASH UPDATE - Had cash and equivalents of $56.4 mln as of end September, enough to fund operations into mid-2026.
XMT-2056 MILESTONE - Achieved $15 mln development milestone from GSK for XMT-2056 clinical trial
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration revenue
$11.009 mln
Q3 EPS
-$1.51
Q3 Net Income
-$7.55 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Mersana Therapeutics Inc is $30.00, about 8.6% above its November 13 closing price of $27.43
Press Release: ID:nGNXc73t1M
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
